Pfizer’s Strategic Acquisitions and Undervalued Position Drive Buy Rating

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Pfizer, retaining the price target of $30.00.

Evan Seigerman has given his Buy rating due to a combination of factors that highlight Pfizer’s strategic positioning and growth potential. The positive Phase 2b obesity data from the VESPER-1 trial, showing a significant placebo-adjusted weight loss of 14.1% at Week 28, provides early validation for Pfizer’s proposed acquisition of Metsera. This data not only supports the efficacy of MET-097i but also underscores Pfizer’s diligence in selecting promising assets for acquisition.
Additionally, Seigerman notes that Pfizer’s shares are currently undervalued compared to its U.S. BioPharma peers, with potential for top-line growth and margin expansion that is not fully appreciated by the market. The company’s strategic use of COVID cash for transformative acquisitions has strengthened its pipeline, positioning it for future success. These factors collectively support the Buy rating, reflecting confidence in Pfizer’s ability to leverage its acquisitions and enhance its market position.

Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Eli Lilly & Co. According to TipRanks, Seigerman has an average return of 3.6% and a 45.90% success rate on recommended stocks.

In another report released on September 23, Jefferies also maintained a Buy rating on the stock with a $34.00 price target.